Journal Information
Vol. 36. Issue. 1.January - February 2016
Pages 1-88
Vol. 36. Issue. 1.January - February 2016
Pages 1-88
Letter to the Editor
DOI: 10.1016/j.nefroe.2016.01.008
Open Access
Atypical haemolytic-uraemic syndrome in a young patient with renal, neurological, ocular and cardiovascular involvement
Síndrome hemolítico urémico atípico en un paciente joven con compromiso renal, neurológico, ocular y cardiovascular
John Fredy Nieto-Ríosa, Lina María Serna-Higuitaa,
Corresponding author
, Estefanía Calle-Boterob, Catalina Ocampo-Kohna, Arbey Aristizabal-Alzatea, Mónica Zuluaga-Quinterob, Gustavo Zuluaga-Valenciaa
a Nefrólogo Hospital Pablo Tobón Uribe–Universidad de Antioquia, Medellín, Colombia
b Residente de Medicina Interna Universidad Pontificia Bolivariana, Medellín, Colombia
Article information
Full Text
Download PDF
Figures (1)
Tables (1)
Table 1. Laboratory results.
Full Text
To the Editor,

We present the case of a 23-year-old man with a 3-month history of headache, loss of vision, loss of appetite, and foamy urine. In the previous week, he had been bedridden, with sensory disturbances, oliguria, and dyspnoea. Upon initial assessment he appeared generally unwell, drowsy, disorientated, tachycardic, hypertensive, and tachypnoeic. He had asterixis, uraemic breath, jugular venous distension, breath sounds with bibasal rales, and oedema of lower limbs. Lab test on admission showed elevated nitrogen products, metabolic acidosis with a wide anion gap, evidence of non-immune microangiopathic haemolytic anaemia and thrombocytopenia (Table 1). Further tests were requested, including ADAMTS13 activity, and infection and immune profiles, which were negative (Table 1). Treatment was started with haemodialysis, parenteral labetalol, red cell transfusion, and plasma exchange. Once uraemia and hypertensive crisis were controlled, ophthalmological examination revealed a marked loss of visual acuity (RE: 20/400+1; LE: 20/1501) and hypertensive retinopathy. On day 7, haemolytic activity was controlled, which allowed discontinuation of plasma exchanges. However, the patient relapsed 48h later, plasma exchanges were restarted and a definitive diagnosis was made of aHUS (Fig. 1). Treatment with eculizumab was initiated, and plasma exchanges were stopped. The patient made adequate progress, with recovery of vision (20/30 in both eyes), however, dialysis had to be maintained. Genetic studies to detect complement mutations associated with aHUS were negative (Table 1). At 9 month follow-up, the patient remained dialysis-dependent; therefore, a diagnosis was made of end-stage renal disease (ESRD) secondary to aHUS, and the workup for renal transplantation was initiated.

Table 1.

Laboratory results.

Urine cytochemistryAppearance  pH  Density  Proteinuria  Red blood cells  Leucocytes  Proteinuria 
Turbid  1.015  >300mg/dL  >50/HPF  21–50/HPF  850mg/day 
Capillary gasespH  HCO3  PCO2  PO2  PaO2/FiO2  Lactate  Base excess 
7.24  9.6mmol/L  22mmHg  121mmHg  242  1.3mmol  −15.7mmol/L 
Renal and metabolic profileCreatinine  BUN  Uric acid  Sodium  Potassium  Chloride  Phosphorus 
19.7mg/dL  128mg/dL  8.5mg/dL  140mEq/L  4.2mEq/L  100mEq/L  8mg/dL 
Corrected calcium  Ionised calcium  Magnesium  Albumin  Glucose  Total cholesterol  HDL-cholesterol 
6.7mg/dl  0.65mmol/L  1.53mg/dL  2.8g/dL  92mg/dL  108mg/dL  31mg/dL 
LDL-cholesterol  Triglycerides  Vitamin D  PTH  Vitamin B12  Ferritin  Folic acid 
63.6mg/dL  61mg/dL  19.3ng/mL  751pg/mL  286pg/mL  551ng/mL  7.7ng/mL 
Haematological profileHaemoglobin  Haematocrit  Leucocytes  Neutrophils  Lymphocytes  Monocytes  Basophils 
5.1g/dL  14%  6.200mm3  80.2%  11.3%  8.1%  0.4% 
Eosinophils  Platelets  Corrected reticulocytes  PBF  LDH  Haptoglobin  ADAMTS13 activity 
0%  82,000mm−3  5.2%  Schistocytes ++  547U/L  10.6mg/dL  74.5% 
PTT  PTT control  PT  INR  Fibrinogen     
3026.1  11.31.04  435mg/dL     
Liver profileTB  DB  IB  AST  ALT  ALP   
1.5mg/dL  0.4mg/dL  1.1mg/dL  22U/L  18U/L  77U/L   
Immunological studiesC3  C4  ANA  ENA  MPOAb  PR3Ab  Direct Coombs 
106mg/dL  28.8mg/dL  Negative  Negative  Negative  Negative  Negative 
Complement genetic study  No pathological mutations were found for: ADAMTS13, C3, CD46, CFB, CFH, CFHR1, CFHR2, CFHR3, CFHR4, CFHR5, CFI, DGKE, PIGA, THBD
Other investigationsProtein electrophoresisHIV  Hepatitis B  Hepatitis C  VDRL  Renal biopsy 
Hypoalbuminemia, non-specific elevation of alpha 1 band and B2Negative  Negative  Negative  Negative  Thrombotic microangiopathy 
Plain CT headEchocardiographyRenal ultrasound
NormalPulmonary hypertension and mild pericardial effusionSmall echogenic kidneys with loss of corticomedullary differentiation

ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANA, antinuclear antibodies; AST, aspartate aminotransferase; BUN, blood urea nitrogen; C3, complement C3; C4, complement C4; CT, computed tomography; DB, direct bilirubin; ENA, antibodies against the extractable nuclear antigens anti-RNP, -Sm, -Ro, and -La; HCO3, serum bicarbonate; HDL cholesterol, high-density lipoprotein cholesterol; HIV, human immunodeficiency virus antibody; HPF, high-power field; IB, indirect bilirubin; LDH, lactate dehydrogenase; LDL cholesterol, low-density lipoprotein cholesterol; MPOAb, anti-myeloperoxidase antibodies; PBF, peripheral blood film; PCO2, partial pressure of carbon dioxide; PO2, partial pressure of oxygen; PR3Ab, anti-proteinase 3 antibodies; PTH, parathyroid hormone; TB, total bilirubin; VDRL, non-treponemal test for syphilis.

Fig. 1.

Results of laboratory investigations during treatment.

Laboratory parameters during treatment: 13 sessions of plasma exchange (blue arrows); total 4 red cell transfusions (red arrow); eculizumab, started on 29 September 2014 (green arrow). The LDH values are at a scale of 1×102 and the platelet values are at a scale of 1×104.


Atypical HUS is an extremely rare chronic genetic disease. It is caused by an abnormality in the regulation of complement and can lead to severe sequelae in multiple organs and even death.1–4 It is characterised by the triad of microangiopathic haemolytic anaemia, thrombocytopenia, and renal failure, though it can affect any organ.1,2 Our patient displayed renal, haematological, neurological, cardiovascular, and ocular involvement; ocular damage is not frequently reported in the literature.1,2

In more than half of the patients with aHUS, it is possible to identify the complement mutation or the mutation in other molecules leading to abnormal complement regulation. However, genetic study is not necessary for diagnosis and initiation of therapy. However genetic studies should be performed to establish prognosis, as some mutations are more aggressive than others. Moreover, genetic study allows more adequate strategy for renal transplantion.1,2,5 Up to 30% of patients have no documented genetic mutation,4,6 as it was the case in our patient.

The treatment of choice for aHUS is eculizumab, a humanised monoclonal antibody that blocks the cleavage of the C5 component of complement, thus preventing the release of the anaphylatoxin C5a and the formation of the membrane attack complex C5b-9. This prevents endothelial damage and the generation of thrombotic microangiopathy.1,7,8 As a prerequisite for starting eculizumab, the patient must be vaccinated against meningococcus and start antibiotic prophylaxis directed against meningococcus whilst the vaccine becomes effective. The earlier eculizumab is started in patients with aHUS, the higher the likelihood of recovery and the fewer sequelae.5,9 Nonetheless, whilst the diagnosis of aHUS is being established, plasma exchanges can stabilise the patient's haemolytic activity, therefore these should be started early if the clinical picture is one of a thrombotic microangiopathy. It should be kept in mind that blood samples should be obtained for ADAMTS13 activity and autoantibody profile prior to plasma exchange to avoid missing other diagnoses.1,5,7 If the definitive diagnosis is aHUS, treatment should be changed to eculizumab, as long-term plasma therapy has not been shown to change the devastating course of aHUS.1,5,9,10 In our patient, plasma exchanges were performed initially, achieving control of haemolytic activity; once the diagnosis of aHUS was established, treatment was changed to eculizumab, achieving a good response with no further need for plasma exchange and no further relapses (Fig. 1). However, the patient was left with the sequela of ESRD.


Atypical HUS is a rare genetic disease that affects children and adults, characterised by the presence of non-immune microangiopathic haemolytic anaemia, thrombocytopenia and multi-organ damage. The clinical course can be devastating and endanger patients’ life and quality of life, leaving them with severe sequelae such as ESRD. Treatment with eculizumab must be started early to halt multi-organ damage and avoid death.

Conflicts of interest

Dr Nieto-Ríos and Dr Serna-Higuita have delivered conferences sponsored by Alexion Pharma. The other authors declare no conflicts of interest with the content of this article.

J. Campistol, M. Arias, G. Ariceta, M. Blasco, M. Espinosa, J. Grinyó, et al.
An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
M. Noris, G. Remuzzi.
Atypical hemolytic-uremic syndrome.
N Engl J Med, 361 (2009), pp. 1676-1687
M. Sallée, L. Daniel, M. Piercecchi, D. Jaubert, V. Fremeaux-Bacchi, Y. Berland, et al.
Myocardial infarction is a complication of factor H-associated atypical HUS.
Nephrol Dial Transplant, 25 (2010), pp. 2028-2032
J. George, C. Nester.
Syndromes of thrombotic microangiopathy.
N Engl J Med, 371 (2014), pp. 654-666
J. Zuber, F. Fakhouri, L. Roumenina, C. Loirat, V. Frémeaux-Bacchi.
FSG for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.
Nat Rev Nephrol, 8 (2012), pp. 643-657
J. George.
Clinical practice. Thrombotic thrombocytopenic purpura.
N Engl J Med, 354 (2006), pp. 1927-1935
National Institute for Health and Care Excellence.
Eculizumab for treating atypical haemolytic uraemic syndrome.
(January 2015),
Available from: [accessed 10.02.15]
R. Rother, S. Rollins, C. Mojcik, R. Brodsky, L. Bell.
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Nat Biotechnol, 25 (2007), pp. 1256-1264
C. Licht, L. Greenbaum, P. Muus, S. Babu, C. Bedrosian, D. Cohen, et al.
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.
Kidney Int, 87 (2015), pp. 1061-1073
M. Noris, J. Caprioli, E. Bresin, C. Mossali, G. Pianetti, S. Gamba, et al.
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.
Clin J Am Soc Nephrol, 5 (2010), pp. 1844-1859

Please cite this article as: Nieto-Ríos JF, Serna-Higuita LM, Calle-Botero E, Ocampo-Kohn C, Aristizabal-Alzate A, Zuluaga-Quintero M, et al. Síndrome hemolítico urémico atípico en un paciente joven con compromiso renal, neurológico, ocular y cardiovascular. Nefrologia. 2016;36:82–85.

Copyright © 2015. Sociedad Española de Nefrología
Nefrología (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.